PNZ5 |
| Katalog-Nr.GC36943 |
PNZ5 ist ein potenter und auf Isoxazol basierender pan-BET-Inhibitor mit hoher SelektivitÄt und Wirksamkeit Ähnlich dem etablierten (+)-JQ1, mit einer KD von 5,43 nM fÜr BRD4(1).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1629277-36-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PNZ5 is a potent and isoxazole-based pan-BET inhibitor with high selectivity and potency similar to the well-established (+)-JQ1, with a KD of 5.43 nM for BRD4(1)[1]. BRD4(1)|5.43 nM (Kd)
[1]. Montenegro RC, et al. BET inhibition as a new strategy for the treatment of gastric cancer. Oncotarget. 2016 Jul 12;7(28):43997-44012.
Average Rating: 5 (Based on Reviews and 11 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *